2024 AGM Presentation
Released
Released
Announcement PDF
Immuron 2024 AGM Presentation
Highlights:
• Global sales increased 172% in FY24 to $4.90m; Record Travelan® sales of $4.86m
• Record monthly sales in October 2024 of $1.49m
• Completed and reported topline results for Travelan® Phase 2 and NMRC’s
Campylobacter clinical trial; planning 2H2025 Phase 3 initiation for Travelan®
• Positive feedback from the FDA to IMM-529 pre-IND filing; planning 2H2025 Phase 2
initiation
• Updated US$400m peak sales US forecast by Lumanity for IMM-529
Melbourne, Australia, November 18, 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian
based and globally integrated biopharmaceutical company is pleased to release its AGM Presentation
ahead of today’s Annual General Meeting which is being held at the office of K&L Gates, Level 25, Rialto
South Tower, 525 Collins Street Melbourne, Victoria, Australia at 11am Australian EST and virtually at
https://bit.ly/IMCAGM2024.
This release has been authorised by the directors of Immuron Limited.
COMPANY CONTACT:
Steven Lydeamore
Chief Executive Officer
Ph: +61 (0)3 9824 5254
info@immuron.com
About Immuron
Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and
commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases.
About Travelan®
Travelan® is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting
travelers’ diarrhea, a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce.
Travelan® is a highly purified tabletized preparation of hyper immune bovine antibodies and other factors, which when
taken with meals bind to diarrhea-causing bacteria and prevent colonization and the pathology associated with travelers’
diarrhea. In Australia, Travelan® is a listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and
is indicated to reduce the risk of Travelers’ Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial.
In Canada, Travelan® is a licensed natural health product (NPN 80046016) and is indicated to reduce the risk of Travelers’
Diarrhea. In the U.S., Travelan® is sold as a dietary supplement for digestive tract protection.
Travelers’ diarrhea (TD)
TD is generally defined as the passage of ≥ 3 unformed stools per 24 hours plus at least one additional symptom (such as
nausea, vomiting, abdominal cramps, fever, blood/mucus in the stools, or fecal urgency) that develop while abroad or within
10 days of returning from any resource-limited destinations (Leung et al., 2006). Diarrhea continues to be the most frequent
health problem among travelers to destinations in lower- and middle-income regions (Steffen, 2017). Deployed US military
personnel, essentially representing a long-term traveller population, are particularly affected given their population dynamics
and the context in which they seek care and treatment (Connor et al., 2012). Diarrhea is the leading infectious disease threat
to the overall health and preparedness of deployed US armed forces, with diarrheagenic E. coli, Campylobacter spp., and
Shigella spp. among the most commonly reported etiologies (Riddle et al., 2006).
Immuron Platform Technology
Immuron’s proprietary technology is based on polyclonal immunoglobulins (IgG) derived from engineered hyper-immune
bovine colostrum. Immuron has the capability of producing highly specific immunoglobulins to any enteric pathogen and our
products are orally active. Bovine IgG can withstand the acidic environment of the stomach and is resistant to proteolysis by
the digestive enzymes found in the Gastrointestinal (GI) tract. Bovine IgG also possesses this unique ability to remain active in
the human GI tract delivering its full benefits directly to the bacteria found there. The underlying nature of Immuron’s platform
technology enables the development of medicines across a large range of infectious diseases. The platform can be used to
block viruses or bacteria at mucosal surfaces such as the Gastrointestinal tract and neutralize the toxins they produce.
IMM-124E (Travelan®)
IMM-124E was developed using Immuron’s platform technology. IMM-124E is produced from the colostrum of birthing cattle
that have been immunised during pregnancy with a vaccine containing the outer antigens of multiple human derived ETEC. A
total of 13 ETEC strains are used in the vaccine to produce high levels of antibodies against selected surface antigens from the
most common strains of ETEC.
The resultant hyperimmune colostrum IMM-124E from ETEC vaccinated cows contains significant levels of polyclonal
antibodies specific for ETEC antigens LPS, CFA-I and Flagellin (Sears et al., 2017).
The antibodies produced in IMM-124E have been found to have a stronger binding and neutralizing activity (than the antibodies
of unvaccinated cattle) against a wide range of LPS antigens including both the variable O-polysaccharide region and the
preserved oligosaccharide core ‘R’ region of LPS from the 13 serotypes used in the ETEC vaccine.
IMM-124E is manufactured into a tablet form referred to as Travelan®.
IMM-529
Immuron is developing IMM-529 as an adjunctive therapy in combination with standard of care antibiotics for the prevention
and/or treatment of recurrent Clostridioides difficile infection (CDI). IMM-529 antibodies targeting Clostridioides difficile (C.
diff) may help to clear CDI infection and promote a quicker re-establishment of normal gut flora, providing an attractive oral
preventative for recurrent CDI.
Immuron is collaborating with Dr. Dena Lyras and her team at Monash University, Australia to develop vaccines to produce
bovine colostrum-derived antibodies. Dairy cows were immunised to generate hyperimmune bovine colostrum (HBC) that
contains antibodies targeting three essential C. diff virulence components. IMM-529 targets Toxin B (TcB), the spores and the
surface layer proteins of the vegetative cells.
This unique 3-target approach has yielded promising results in pre-clinical infection and relapse models, including (1)
Prevention of primary disease (80% P =0.0052); (2) Protection of disease recurrence (67%, P <0.01) and (3) Treatment of
primary disease (78.6%, P<0.0001; TcB HBC). Importantly IMM-529 antibodies cross-react with whole cell lysates of many
different human strains of C. diff including hypervirulent strains.
To our knowledge, IMM-529 is, to date, the only investigational drug that has shown therapeutic potential in all three phases
of the disease (Hutton et al., 2017).
References
Connor P, Porter CK, Swierczewski B and Riddle MS. Diarrhea during military deployment: current concepts and future directions. Curr Opin
Infect Dis. 25(5): 546-54; 2012.
Hutton, M.L., Cunningham, B.A., Mackin, K.E. et al. Bovine antibodies targeting primary and recurrent Clostridium difficile disease are a
potent antibiotic alternative. Sci Rep 7, 3665 (2017). https://doi.org/10.1038/s41598-017-03982-5
Leung AK, Robson WL, Davies HD. Travelers’ diarrhea. Adv Ther. Jul-Aug; 23(4): 519-27; 2006
Otto W, Najnigier B, Stelmasiak T and Robins-Browne RM. Randomized control trials using a tablet formulation of hyperimmune bovine
colostrum to prevent diarrhea caused by enterotoxigenic Escherichia coli in volunteers Scandinavian Journal of Gastroenterology 46: 862–
868; 2011.
Riddle MS, Sanders JW, Putnam SD, and Tribble DR. Incidence, etiology, and impact of diarrhea among long-term travelers’ (US military and
similar populations): A systematic review. American Journal of Tropical Medicine and Hygiene. 74(5): 891-900; 2006.
Sears KT, Tennant SM, Reymann MK, Simon R, Konstantopolos N, Blackwelder WC, Barry EM and Pasetti MF. Bioactive Immune Components
of Anti-Diarrheagenic Enterotoxigenic Escherichia coli Hyperimmune Bovine Colostrum products. Clinical and Vaccine Immunology. 24 (8) 114; 2017.
Steffen R. Epidemiology of travelers' diarrhea. J Travel Med. 24(suppl_1): S2-S5; 2017.
For more information visit: https://www.immuron.com.au/ and https://www.travelan.com
FORWARD-LOOKING STATEMENTS:
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product
development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations
and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition, and stock value. Factors that could
cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and
maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing
of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract,
integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent
and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events,
conditions, or circumstances on which any such statement is based, except as required by law.
AGM
PRESENTATION
18 NOVEMBER, 2024
S t e v e n Ly d e a m o r e - C E O
NASDAQ: IMRN
ASX: IMC
1
SAFE HARBOR STATEMENT
C e r ta i n state m e n t s m a d e i n t h i s p re s e nta t i o n a re fo r wa rd - l o o k i n g state m e n t s a n d a re
b a s e d o n I m m u ro n ’s c u r re nt ex p e c tat i o n s , e st i m ate s a n d p ro j e c t i o n s . Wo rd s s u c h a s
“a nt i c i p a t e s ,” “ex p e c t s ,” “ i nte n d s ,” “ p l a n s ,” “ b e l i e ve s ,” “s e e ks ,” “e st i m a te s ,” “g u i d a n c e ”
a n d s i m i l a r ex p re s s i o n s a re i nte n d e d to i d e nt i f y fo r wa rd - l o o k i n g state m e n t s .
A l t h o u g h I m m u ro n b e l i e v e s t h e fo r wa rd - l o o k i n g state m e n t s a re b a s e d o n
re a s o n a b l e a s s u m p t i o n s , t h ey a re s u b j e c t to c e r ta i n r i s ks a n d u n c e r ta i n t i e s ,
s o m e o f w h i c h a re b eyo n d I m m u ro n ’s c o nt ro l , i n c l u d i n g t h o s e r i s ks o r
u n c e r ta i n t i e s i n h e re n t i n t h e p ro c e s s o f b o t h d e ve l o p i n g a n d c o m m e rc i a l i z i n g
te c h n o l o g y. A s a re s u l t , a c t u a l re s u l t s c o u l d m ate r i a l l y d i ffe r f ro m t h o s e
ex p re s s e d o r fo re ca ste d i n t h e fo r wa rd - l o o k i n g state m e n t s .
T h e fo r wa rd - l o o k i n g state m e n t s m a d e i n t h i s p re s e n ta t i o n re l ate o n l y to
e ve nt s a s o f t h e d ate o n w h i c h t h e state m e n t s a re m a d e . I m m u ro n w i l l n o t
u n d e r ta ke a ny o b l i gat i o n to re l e a s e p u b l i c l y a ny re v i s i o n s o r u p d ate s to
t h e s e fo r wa rd - l o o k i n g state m e n t s to ref l e c t e ve nt s , c i rc u m sta n c e s o r
u n a nt i c i p a te d e ve nt s o c c u r r i n g a f te r t h e d ate o f t h i s p re s e nta t i o n exc e p t a s
re q u i re d b y l aw o r b y a ny a p p ro p r i a te re g u l ato r y a u t h o r i t y.
F Y 2 0 2 5 re s u l t s i n t h i s p re s e nta t i o n a re s u b j e c t to a u d i t re v i e w.
2
EXECUTIVE SUMMARY
Immuron Ltd (ASX:IMC) (NASDAQ:IMRN) is a globally integrated biopharmaceutical company focused on
developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases
Company
Overview
Business
Update
•
Platform Technology: capable of producing highly specific orally active immunoglobulins to any enteric pathogen
•
Two commercially available oral immunotherapeutic products – Travelan® and Protectyn®
•
•
Two pipeline assets in three clinical programs
Market capitalisation of $17.6 million as of 25 October 2024 with cash and cash equivalents balance of $11.7 million as of 30 June
2024
•
The FY24 sales and marketing strategy of distribution, awareness, education and visibility via consumer media and the trade is
working
•
Travel continues its momentum and Travelan is increasing market share of the antidiarrheal category
•
Global sales increased 172% in FY24 to $4.90 million; Record Travelan® sales of $4.86 million
•
Travelan® was the #1 SKU in the Antidiarrheal category across Chemist Warehouse pharmacy in Australia1
•
Record monthly sales in October 2024 of $1.49 million
•
Completed and reported topline results for Travelan® Phase 2 and NMRC’s Campylobacter clinical trial; planning 2H2025 Phase 3
initiation for Travelan®
•
Positive feedback from the FDA to IMM-529 pre-IND filing; planning 2H2025 Phase 2 initiation
1. IQVIA Australia Pharmacy Scan – Antidiarrheal segment, value sales 4 weeks to 28 September 2024
3
NAVAL MEDICAL RESEARCH COMMAND TRIAL
NMRC experimental campylobacter/ETEC vaccine
o
The trial was funded by the Naval Medical Research Command (NMRC). Immuron’s produced a hyperimmune bovine colostrum (HBC)
trial product using the NMRC vaccine which was tested in a controlled human infection model study. The results of this clinical trial are
unrelated to Travelan® and do not impact Immuron’s plans to hold an end of Phase 2 meeting with the U.S. Food and Drug
Administration (FDA). Nor does this NMRC trial impact on Immuron’s commercialization strategy for Travelan®.
o
Trial Conclusions:
o
CampETEC was well-tolerated
o
No moderate or severe adverse events were reported
o
CampETEC did not significantly prevent campylobacteriosis
o
Regimen dose of CampETEC not enough / too many bacteria in the inoculum
o
Targeting the polysaccharide capsule may not prevent epithelial cell invasion
o
Future Direction:
o
NMRC to evaluate:
o
New vaccine candidates which target Campylobacter (e.g. whole cells and Surface layer proteins of the flagellum, a whiplike appendage that enables bacterial motility) for the development of HBC
o
USD $2.3 million funding for NMRC and Walter Reed Army Institute of Research (WRAIR) approved by the U.S. Department of
Defense
o
This work will utilize the extensive experience of the US Department of Defense human infectious disease vaccine
programs, and one part of this program will target key protective antigens of the enteric bacterial pathogen
campylobacter
4
STRONG PIPELINE WITH NEAR TERM MILESTONES
Immuron’s Clinical Programs
Compound or
brand name
Indication
IMM-124E
Travelan®
Traveler’s
Diarrhea ETEC
challenge
IMM-529
Clostridioides
difficile
Infection &
Recurrence
Phase
I
Phase
II
Phase
III
Market
Our Partners’ Clinical Programs
Compound or
brand name
Travelan®
Partner
Phase
I
Phase
II
Phase
III
Market
Uniformed Services University
5
TRAVELAN® PROGRESSES TOWARDS PHASE 3
Travelan® (IMM-124E) Phase 2
o
o
o
o
o
o
o
o
o
o
Travelan® IND Approval – December 2022
Study Initiation – May 2023
First cohort recruitment completed – July 2023
Presentations at Military Health System Research Symposium – August 2023
Second cohort recruitment completed – October 2023
Completion of In-patient phase – October 2023
Topline Results – March 2024
Anticipated Clinical Study Report – December 2024
Anticipated End of Phase 2 FDA meeting – 1H 2025
Anticipated initiation of Phase 3 clinical study – 2H 2025
US Uniformed Services University Traveller’s Diarrhoea Clinical Field Trial
o
o
o
o
o
o
USU’s Infectious Diseases Clinical Research Program (IDCRP) are conducting a randomized
clinical trial to evaluate the efficacy of Travelan® against placebo for Traveller’s Diarrhoea
866 study participants (433 per arm)
50% recruitment milestone – October 2023
85% recruitment milestone – September 2024
Anticipated completion of recruitment – December 2024
Anticipated topline results – April 2025
6
IMM-529 PROGRESSION TO PHASE 2
IMM-529 Clinical Development for Treatment of C. difficile Infections
o
o
o
o
o
o
o
o
o
o
o
o
Opportunity Assessment completed by
C. difficile infection (CDI) affects just over ~400,000 people in the US annually
Sizable number of patients who experience at least one recurrence (~20-25%),
Many patients experience multiple recurrences, creating persistent unmet need for novel therapies
to address recurrences
Infectious disease experts reacted favorably to the IMM-529 MOA, and its ability to target three
elements of the CDI infection –the spores, vegetative cells, and Toxin B
Non-antibiotic treatments (such as IMM-529) are appealing to experts
600mg solid dose active formulation development – February 2023
cGMP manufacture – December 2023
FDA pre-IND submission – July 2024
Positive FDA feedback to pre-IND submission – September 2024
Updated peak sales US forecast by
for IMM-529: from US$93 million to US$400 million
Anticipated initiation of Phase 2 clinical trial – 2H 2025
7
IMMURON’S CLINICAL PROGRAMS – OPPORTUNITY ASSESSMENT
Opportunity
Lumanity*
Corporate
Assessment for IMM-124E
›
›
›
›
Immuron’s development of IMM-124E (hyperimmune
bovine colostrum) as a prescription medication has
the potential to address this unmet need
Primary care physicians (PCP)s impressed with clinical
efficacy endpoint targets demonstrating > 80%
protection against the development of diarrhea.
If base case efficacy targets are reached, IMM-124E
would mostly be used by travelers going to the
highest risk areas (e.g., rural Central
America/Asia/Africa).
Based on the estimated market size and pricing, the
base case yearly revenue in USA for IMM-124E is
projected at US$102M.
Reaching higher efficacy goals could broaden use.
Compound or brand name
Indication
IMM-124E - Travelan®
Traveler’s Diarrhea ETEC challenge
IMM-529
Clostridioides difficile Infection (CDI) &
Recurrence
›
›
Opportunity
Lumanity
Corporate
Assessment for IMM-529
›
›
›
Infectious disease experts reacted favorably to the IMM-529
MOA, and its unique ability to target three elements of the
rCDI infection – the spores, vegetative cells, and Toxin B
If IMM-529 can achieve a significant reduction in
recurrences among patients with CDI, it can reach peak
revenues of ~US$400 million in USA
Based on new information about the overall CDI market and
IMM-529’s potential to be used earlier in the treatment
algorithm (based on approvals for treatment and prevention
of recurrence)
Derived wholly from secondary research, price target
increased to Vowst level, as a second mover IMM-529 is
projected to reach a 30% share of the advanced treatment
market
Phase I
Phase II
Lumanity, a leading lifescience consulting company: https://lumanity.com/company/our-story/
Phase III
Market
8
CONTINUED STRONG SALES GROWTH
o
Global sales increased by 172% in the 2024 fiscal year to a
record A$4.90 million compared to A$1.80 million in FY23
o
Record monthly sales in October 2024 of $1.49 million
o
Australia
o
FY24: a record A$3.75 million; up 223%
o
Q1, FY25: A$1.01 million
o
October 2024: A$1.16 million
o
Travelan® was the #1 SKU in the Antidiarrheal category
across Chemist Warehouse in Australia1
o
USA
o
FY24: a record A$1.08 million; up 67%
o
Q1, FY25: A$0.28 million
o
October 2024: A$0.17 million
o
Canada
o
FY24: A$0.08 million
o
Q1, FY25: A$0.17 million
o
October 2024: a monthly record A$0.15 million
1. IQVIA Australia Pharmacy Scan – Antidiarrheal segment, value sales 4 weeks to 28 September 2024
9
EXPANSION OF TRAVELAN® DISTRIBUTION
10
CONSUMER MARKETING ACTIVITY DRIVING TRAVELAN®
SALES GROWTH
We continue to drive awareness,
consideration and engagement
o Ranging across major retailers
(Australia, Canada)
o In-store positioning and
promotion
o Retailer catalogues
o Search and social media
marketing
o Social competitions
o User generated content
o Influencer program
o HCP user generated activity
o Amazon Prime sales promotions
o Amazon sponsored brand ads
11
STEVEN LYDEAMORE
CHIEF EXECUTIVE OFFICER
IMMURON LIMITED
CONTACT INFORMATION:
EMAIL: STEVE@IMMURON.COM
PHONE: AUSTRALIA: +613 8892 4854
12
Scientific references
Travelan® (IMM-124E)
Travelan® has been shown to reduce both the incidence and severity of ETECinduced diarrhea in up to 90% of volunteers
Scandinavian Journal of Gastroenterology, 46:7-8, 862-868, DOI: 10.3109/00365521.2011.574726
Clinical Evaluation of Travelan® an Oral Prophylactic for Prevention of Travelers’
Diarrhea in Active Duty Military Service Assigned Abroad.
Military Health System Research Symposium 14-17 Aug 2023_Abstract 1
Travelan as a broad Spectrum anti-bacterial
Immuron Limited, 29 April, 2011
Travelan® demonstrates broad reactivity to Vibrio cholera strains from Southeast
Asia indicating broad potential for prevention of traveler’s diarrhea
US Department of Defense, Armed Forces Research Institute of Medical Sciences (AFRIM), 4 September, 2019
Travelan® prevented clinical shigellosis (bacillary dysentery) in 75% of Travelan®
treated animals compared to placebo and demonstrated a significant clinical benefit
US Department of Defense, Armed Forces Research Institute of Medical Sciences (AFRIM), 5 September, 2018
Travelan® able to bind and was reactive to 60 clinical isolates of each bacteria,
Campylobacter, ETEC, and Shigella
US Department of Defense, Armed Forces Research Institute of Medical Sciences (AFRIM), 30 January, 2017
Bioactivity and efficacy of a hyperimmune bovine colostrum product- Travelan,
against shigellosis in a non-Human primate model (Macaca mulatta)
Islam D, Ruamsap N, Imerbsin R, Khanijou P, Gonwong S, Wegner MD, et al. (2023) Bioactivity and efficacy of a hyperimmune bovine
colostrum product- Travelan, against shigellosis in a non-Human primate model (Macaca mulatta). PLoS ONE 18(12): e0294021.
Bioactive Immune Components of Travelan®
Clin Vaccine Immunol 24:e00186-16. https://doi.org/10.1128/CVI.00186-16
Hyperimmune bovine colostrum containing lipopolysaccharide antibodies (IMM124E) has a non-detrimental effect on gut microbial communities in unchallenged
mice
Infect Immun. 2023 Nov; 91(11): e00097-23.
Administration of the Hyper-immune Bovine Colostrum Extract IMM-124E
Ameliorates Experimental Murine Colitis
Journal of Crohn's and Colitis, Volume 13, Issue 6, June 2019, Pages 785–797, https://doi.org/10.1093/ecco-jcc/jjy213
IMM-529
Bovine antibodies targeting primary and recurrent Clostridium difficile disease are a
potent antibiotic alternative
13
Sci Rep 7, 3665 (2017). https://doi.org/10.1038/s41598-017-03982-5
Share your feedback
Discover